Marvel Biosciences Corp. (MRVL.V)
CAD 0.16
(10.34%)
CAD 0.16
(10.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 443.37 Thousand CAD | 174.74% |
| 2022 | -593.2 Thousand CAD | 75.21% |
| 2021 | -2.39 Million CAD | -964.52% |
| 2020 | -224.81 Thousand CAD | -3507.35% |
| 2019 | -6232.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.28 Million CAD | 39.03% |
| 2024 Q1 | 683.01 Thousand CAD | 54.05% |
| 2024 Q2 | 922.32 Thousand CAD | 35.04% |
| 2023 Q3 | -153.42 Thousand CAD | 48.57% |
| 2023 FY | 443.37 Thousand CAD | 174.74% |
| 2023 Q1 | -535.92 Thousand CAD | 9.66% |
| 2023 Q2 | -298.32 Thousand CAD | 44.33% |
| 2023 Q4 | 443.37 Thousand CAD | 388.98% |
| 2022 Q1 | -2.11 Million CAD | 11.45% |
| 2022 FY | -593.2 Thousand CAD | 75.21% |
| 2022 Q4 | -593.2 Thousand CAD | 7.79% |
| 2022 Q2 | -859.17 Thousand CAD | 59.46% |
| 2022 Q3 | -643.32 Thousand CAD | 25.12% |
| 2021 Q4 | -2.39 Million CAD | -510.19% |
| 2021 Q3 | -392.19 Thousand CAD | 0.0% |
| 2021 FY | -2.39 Million CAD | -964.52% |
| 2020 FY | -224.81 Thousand CAD | -3507.35% |
| 2019 FY | -6232.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arch Biopartners Inc. | 4.18 Million CAD | 89.405% |
| Covalon Technologies Ltd. | -7.23 Million CAD | 106.131% |
| Hemostemix Inc. | 4.16 Million CAD | 89.357% |
| Universal Ibogaine Inc. | 1.01 Million CAD | 56.172% |
| Kane Biotech Inc. | 7.52 Million CAD | 94.109% |
| MedMira Inc. | 9.25 Million CAD | 95.211% |
| NervGen Pharma Corp. | -11.46 Million CAD | 103.868% |
| XORTX Therapeutics Inc. | -4.53 Million CAD | 109.786% |